| Naslov: | Induction chemotherapy and concurrent chemoradiotherapy for larynx preservation in laryngeal and hypopharyngeal cancer |
|---|
| Avtorji: | ID Strojan, Primož (Avtor)
ID Plavc, Gaber (Avtor)
ID Šifrer, Robert (Avtor)
ID Jereb, Simona (Avtor)
ID Lanišnik, Boštjan (Avtor)
ID Kokalj, Marko (Avtor)
ID Grošelj, Aleš (Avtor)
ID Grašič-Kuhar, Cvetka (Avtor) |
|---|
| Datoteke: |  URL - Izvorni URL, za dostop obiščite https://doi.org/10.2478/raon-2025-0055
URL - Izvorni URL, za dostop obiščite https://reference-global.com/article/10.2478/raon-2025-0055
 PDF - Predstavitvena datoteka, prenos (883,77 KB)
MD5: BEA12588AF1F76842D5E5BB5A12A8BF7
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  OI - Onkološki inštitut Ljubljana
 UKC MB - Univerzitetni klinični center Maribor
|
|---|
| Povzetek: | To test the hypothesis that clinical tumor response after a single cycle of induction chemotherapy (ICT) can reliably differentiate between chemo-/radiosensitive and resistant tumors in the larynx preservation setting. Patients and methods Treatment consisted of docetaxel/cisplatin/5-fluorouracil (TPF) ICT followed by concurrent chemoradiotherapy (cCRT) with weekly cisplatin. The response of the primary tumor was assessed by transnasal endoscopy after the first ICT cycle. Results 37/39 (95%) patients with laryngeal (46%) or hypopharyngeal (54%) carcinoma responded to one cycle of ICT, and two patients were referred for salvage surgery. Laryngectomy-free survival at 2 and 5 years was 87% and 75%, respectively. The corresponding rates for locoregional control (and also for disease-free survival) were 79% and 70% and for overall survival 92% and 82%. Conclusions Clinical assessment of tumor response to one cycle of TPF ICT serves as a valid and easy-to-use predictor of tumor sensitivity to platinum-based cCRT. |
|---|
| Ključne besede: | induction chemotherapy, chemoradiotherapy, arynx preservation |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Poslano v recenzijo: | 21.07.2025 |
|---|
| Datum sprejetja članka: | 05.09.2025 |
|---|
| Datum objave: | 01.12.2025 |
|---|
| Kraj izida: | Ljubljana |
|---|
| Založnik: | Association of Radiology and Oncology |
|---|
| Leto izida: | 2025 |
|---|
| Št. strani: | str. 579-588 |
|---|
| Številčenje: | Vol. 59, no. 4 |
|---|
| Izvor: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-25286  |
|---|
| UDK: | 616-006 |
|---|
| ISSN pri članku: | 1318-2099 |
|---|
| DOI: | 10.2478/raon-2025-0055 |
|---|
| COBISS.SI-ID: | 262922755 |
|---|
| Avtorske pravice: | by Authors |
|---|
| Opomba: | Soavtorji: Gaber Plavc, Robert Sifrer, Simona Jereb, Bostjan Lanisnik, Marko Kokalj, Ales Groselj, Cvetka Grasic Kuhar;
|
|---|
| Datum objave v DiRROS: | 16.01.2026 |
|---|
| Število ogledov: | 119 |
|---|
| Število prenosov: | 99 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
